Future research should focus on mechanistic validation of cytoplasmic p73 regulation, functional assessment of isoform-specific activity, and development of therapeutic approaches to restore p73 tumour-suppressive function, ultimately improving outcomes for patients with TP53-mutant breast cancers. The gene discussed is TP73; the disease is neoplasm.